目前已经分离和提纯了20多种血管生成因子,其中最重要的是血管内皮生长因子(vaseular endothelial growth faetor,VEGF)。既往认为vEGFR只特异地表达于内皮细胞,且只有内皮细胞对vEGF有应答[‘]。
基于2个网页-相关网页
由美国食品与药品管理局批准治疗转移克隆癌的贝伐单抗,是血管内皮生长因子的单克隆抗体。
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, is approved by the US Food and Drug Administration for metastatic colon cancer.
目的:在众多血管再生性因子中,血管内皮生长因子及其受体2是公认的促使血管生成的关键性因素。
OBJECTIVE Vascular endothelial growth factor VEGF and its receptor 2 are the generally accepted key factor on the formation of blood vessel in numerous blood vessel regeneration factors.
采用化学治疗药物(贝伐单抗,是中和血管内皮生长因子的人源化抗体)治疗可导致蛋白尿和肾功能损害。
Treatment with the chemotherapeutic agent bevacizumab, a humanized mab that neutralizes vascular endothelial growth factor, can lead to proteinuria and renal damage.
If you could introduce that gene you'd make the chemical, in this case it's a protein called vascular endothelial growth factor.
通过导入一种生成特殊化学物质的基因,这种疗法中指的是一种蛋白,叫做血管内皮生长因子
应用推荐